

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 July 2025 (17.07.2025)



(10) International Publication Number
WO 2025/149998 A1

(51) International Patent Classification:

A61K 9/00 (2006.01) *A61K 47/08* (2006.01)
A61K 9/08 (2006.01) *A61K 47/10* (2017.01)
A61K 31/5575 (2006.01) *A61K 47/12* (2006.01)
A61K 31/57 (2006.01) *A61K 47/22* (2006.01)

(21) International Application Number:

PCT/IB2025/050381

(22) International Filing Date:

13 January 2025 (13.01.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

202421002308 11 January 2024 (11.01.2024) IN

(71) Applicant: **GLENMARK SPECIALTY S.A.** [CH/CH];

Place du Port 2, 2000 Neuchâtel (CH).

(72) Inventors: **OTAVKAR, Roopali**; Glenmark Pharmaceuti-

cals Limited, M-4, Taloja MIDC, Taluka Panvel, District Raigad, Maharashtra, Navi Mumbai 410208 (IN). **ABRAHAM, Jaya**; Glenmark Pharmaceuticals Limited, M-4, Taloja MIDC, Taluka Panvel, District Raigad, Maharashtra, Navi Mumbai 410208 (IN). **BANGAR, Ganesh**; Glenmark Pharmaceuticals Limited, M-4, Taloja MIDC, Taluka Panvel, District Raigad, Maharashtra, Navi Mumbai 410208 (IN). **DHUPPAD, Ulhas**; Glenmark Pharmaceuticals Limited, M-4, Taloja MIDC, Taluka Panvel, District Raigad, Maharashtra, Navi Mumbai 410208 (IN). **KULKARNI, Abhay**; Glenmark Research Centre, Plot No. A-607, T.T.C. Industrial Area, M.I.D.C., Mahape, Maharashtra, Navi Mumbai 400709 (IN). **GANDHI, Maulik**; Glenmark Research Centre, Plot No. A-607, T.T.C. Industrial Area, M.I.D.C., Mahape, Maharashtra, Navi Mumbai 400709 (IN). **UDUPA, Venkatesh**; Glenmark Research Centre, Plot No. A-607, T.T.C. Industrial Area, M.I.D.C., Mahape, Maharashtra, Navi Mumbai 400709 (IN). **PAWAR, Pramod**; Glenmark Research Centre, Plot No. A-607, T.T.C. Industrial Area, M.I.D.C., Mahape, Maharashtra, Navi Mumbai 400709 (IN). **CHOPADE, Atul**; Glenmark Pharmaceuticals Limited, M-4, Taloja MIDC, Taluka Panvel, District Raigad, Maharashtra, Navi Mumbai 410208 (IN).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: TOPICAL COMPOSITION COMPRISING CLASCOTERONE AND LATANOPROST FOR ALOPECIA

(57) Abstract: The present invention relates to the topical pharmaceutical composition comprising about 0.001% w/w to about 1% w/w latanoprost and about 1% w/w to about 15% w/w cortexolone-17 α -propionate and a pharmaceutically acceptable vehicle comprising one or more solvent and process of its preparation. The invention further relates to the method wherein the composition is suitable for preventing and/or treating hair loss and/or stimulating hair growth. in patients suffering from alopecia, in particular androgenic alopecia (AGA).



WO 2025/149998 A1